Related Experiment Video
Updated: May 15, 2026
03:42
A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
Published on: March 29, 2024
Modulating the Secretome of Fat to Treat Heart Failure
Lorien G Salyer1,2, Yajing Wang3, Xinliang Ma4
1Division of Cardiology, Department of Medicine (L.G.S., T.A.M.), University of Colorado Anschutz Medical Campus, Aurora, CO.
Circulation Research
|May 22, 2025
Summary
Obesity contributes to heart failure through inflammation and altered fat secretomes. Understanding these mechanisms may reveal new therapeutic targets for heart failure.
Area of Science:
- Cardiology
- Metabolic Disease
- Obesity Research
Background:
- Heart failure affects over 6 million US individuals, causing high mortality and costs.
- Obesity is a significant risk factor for heart failure development.
- Excess adipose tissue contributes to heart failure through inflammation and altered endocrine function.
Purpose of the Study:
- To review current obesity therapies and their cardiac effects.
- To explore mechanisms of fat-heart communication via secreted factors.
- To identify potential therapeutic targets for heart failure.
Main Methods:
- Literature review of obesity therapies and their impact on the heart.
- Analysis of mechanisms linking adipose tissue secretomes to cardiac dysfunction.
- Identification of druggable targets in the fat-heart signaling axis.
Main Results:
- Adipose tissue-driven inflammation promotes cardiometabolic comorbidities like hypertension.
- Dysfunctional fat secretomes induce cardiac inflammation and oxidative stress.
- Current obesity therapies have varying effects on cardiac health.
Conclusions:
- Fat-heart communication via the secretome plays a critical role in heart failure pathogenesis.
- Targeting specific nodes in this communication circuit offers potential for novel heart failure therapies.
- Further research into obesity's impact on cardiac function is warranted.
Related Concept Videos
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.